22 news items
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
ANNX
17 Jun 24
. Annexon's novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic
Annexon Announces Pricing of $125 Million Underwritten Public Offering
ANNX
5 Jun 24
approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide
Annexon Announces Proposed Public Offering of Common Stock
ANNX
4 Jun 24
. Annexon's novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic
Needham Reiterates Buy on Annexon, Maintains $16 Price Target
ANNX
4 Jun 24
Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $30 Price Target
ANNX
4 Jun 24
HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.
606jv14ofo91zbls8gj7aagz
AGEN
ANNX
BOOT
4 Jun 24
Clinch upgraded Upstart from Sell to Neutral and raised the price target from $22.5 to $25.5.
Now Read This: Best Buy, McKesson And 2 Other Stocks Insiders Are Selling
8lx309pfe
ANNX
3 Jun 24
diseases of the body, brain, and eye. Annexon's novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade
sbpsyn495oilyqkm1eqinhmin6gmeac
ANNX
16 May 24
novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic
fojz2w3bra8h8
ANNX
15 May 24
Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and lowers the price target from $12 to $10.
kmihfurijdsmlzp1g2o8r2o4g397fgg61m
ANNX
14 May 24
HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.
nwlpfb9i z0xc2vtfhfxblg0iamdejn70z3h9ag8d12bq2svrbcc75
ANNX
13 May 24
Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
9s02uyhs 33qdu2oao
ANNX
7 May 24
-mediated neuroinflammatory diseases of the body, brain, and eye. Annexon's novel scientific approach targets upstream C1q to block the classical
u48z cpegv
ANNX
1 May 24
diseases of the body, brain, and eye. Annexon's novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before
74fipxw6 z78dex0h286ywum7hy
ANNX
16 Apr 24
novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates
yxbs6 3y3qy99eo9u
ANNX
11 Apr 24
Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
kccjenyet1pm3b1xdx4w5bt7pkrinu5
ANNX
1 Apr 24
Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and maintains $12 price target.
yh7 oerrwpyq
ANNX
1 Apr 24
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $11 to $13.
9ldnxbqa5vjtm0fhuq3qjgr3n4ie80 17ovhhv4yhic1i02r
AKBA
ANNX
CTAS
27 Mar 24
Jefferies upgraded the stock from Hold to Buy and raised its price target from $1.40 to $10.
Annexon, Inc
ja6fx99rb1wl40x qx
ANNX
27 Mar 24
HC Wainwright & Co. analyst Andrew Fein maintains Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.
h82wymg3fyz1g
ANNX
27 Mar 24
Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $11 to $12.